Tolerance: Is It Achievable in Pediatric Solid Organ Transplantation?

Pediatric Clinics of North America

Volumn 57, Issue 2, 2010, Pages 523-538

  Seyfert Margolis, Vicki ^a   Feng, Sandy ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Allo immune response; Immunosuppression withdrawal; Pediatric solid organ transplantation; Tolerance

Indexed keywords

CALCINEURIN INHIBITOR; CD28 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ALLOIMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CLINICAL TRIAL; CYTOKINE PRODUCTION; DONOR SELECTION; DRUG EFFICACY; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HISTOINCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NATURAL KILLER T CELL; NONHUMAN; ORGAN TRANSPLANTATION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SOLID ORGAN TRANSPLANTATION; TH17 CELL;

BIOLOGICAL MARKERS; CHILD; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MODELS, IMMUNOLOGICAL; MONITORING, IMMUNOLOGIC; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 77950979410     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.01.015     Document Type: Review

References (59)

1. Guild W.R., Harrison J.H., Merrill J.P., et al. Successful homotransplantation of the kidney in an identical twin. Trans Am Clin Climatol Assoc 1955, 67:167-173.
2. Michon L., Hamburger J., Oeconomos N., et al. Presse Med 1953, 61(70):1419-1423.
3. Billingham R.E., Brent L., Medawar P.B. Actively acquired tolerance of foreign cells. Nature 1953, 172(4379):603-606.
4. Bartosh S.M., Ryckman F.C., Shaddy R., et al. A national conference to determine research priorities in pediatric solid organ transplantation. Pediatr Transplant 2008, 12(2):153-166.
5. Traum A.Z., Kawai T., Vacanti J.P., et al. The need for tolerance in pediatric organ transplantation. Pediatrics 2008, 121(6):1258-1260.
6. von Boehmer H. The developmental biology of T lymphocytes. Annu Rev Immunol 1988, 6:309-326.
7. Janeway's immunobiology 2007, Garland Science, New York, London. 7th edition. K. Murphy, P. Travers, M. Walport (Eds.).
8. Dunon D., Courtois D., Vainio O., et al. Ontogeny of the immune system: gamma/delta and alpha/beta T cells migrate from thymus to the periphery in alternating waves. J Exp Med 1997, 186(7):977-988.
9. Melchers F., ten Boekel E., Seidl T., et al. Repertoire selection by pre-B-cell receptors and B-cell receptors, and genetic control of B-cell development from immature to mature B cells. Immunol Rev 2000, 175:33-46.
10. Peterson P., Org T., Rebane A. Transcriptional regulation by AIRE: molecular mechanisms of central tolerance. Nat Rev Immunol 2008, 8(12):948-957.
11. Goodnow C.C., Crosbie J., Jorgensen H., et al. Induction of self-tolerance in mature peripheral B lymphocytes. Nature 1989, 342(6248):385-391.
12. Russell D.M., Dembic Z., Morahan G., et al. Peripheral deletion of self-reactive B cells. Nature 1991, 354(6351):308-311.
13. Tinckam K.J., Sayegh M.H. Transplantation tolerance in pediatric recipients: lessons and challenges. Pediatr Transplant 2005, 9(1):17-27.
14. Wells A.D. New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting. J Immunol 2009, 182(12):7331-7341.
15. Sakaguchi S., Yamaguchi T., Nomura T., et al. Regulatory T cells and immune tolerance. Cell 2008, 133(5):775-787.
16. Feng G., Chan T., Wood K.J., et al. Donor reactive regulatory T cells. Curr Opin Organ Transplant 2009, 14(4):432-438.
17. Fehr T., Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl Int 2008, 21(12):1118-1135.
18. Millan M.T., Shizuru J.A., Hoffmann P., et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002, 73(9):1386-1391.
19. Scandling J.D., Busque S., Dejbakhsh-Jones S., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008, 358(4):362-368.
20. Fudaba Y., Spitzer T.R., Shaffer J., et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 2006, 6(9):2121-2133.
21. Kawai T., Cosimi A.B., Spitzer T.R., et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008, 358(4):353-361.
22. Buhler L., Alwayn I.P., Appel J.Z., et al. Anti-CD154 monoclonal antibody and thromboembolism. Transplantation 2001, 71(3):491.
23. Nagahama K., Fehervari Z., Oida T., et al. Differential control of allo-antigen-specific regulatory T cells and effector T cells by anti-CD4 and other agents in establishing transplantation tolerance. Int Immunol 2009, 21(4):379-391.
24. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105(12):4743-4748.
25. Haxhinasto S., Mathis D., Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008, 205(3):565-574.
26. Gao W., Lu Y., El Essawy B., et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007, 7(7):1722-1732.
27. Yoshizawa A., Ito A., Li Y., et al. The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc 2005, 37(1):37-39.
28. Owens M.L., Maxwell J.G., Goodnight J., et al. Discontinuance of immunosuprression in renal transplant patients. Arch Surg 1975, 110(12):1450-1451.
29. Zoller K.M., Cho S.I., Cohen J.J., et al. Cessation of immunosuppressive therapy after successful transplantation: a national survey. Kidney Int 1980, 18(1):110-114.
30. Starzl T.E., Demetris A.J., Trucco M., et al. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993, 55(6):1272-1277.
31. Brouard S., Mansfield E., Braud C., et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 2007, 104(39):15448-15453.
32. Roussey-Kesler G., Giral M., Moreau A., et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 2006, 6(4):736-746.
33. Bertolino P., McCaughan G.W., Bowen D.G. Role of primary intrahepatic T-cell activation in the 'liver tolerance effect'. Immunol Cell Biol 2002, 80(1):84-92.
34. Crispe I.N. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003, 3(1):51-62.
35. Calne R.Y., Sells R.A., Pena J.R., et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969, 223(205):472-476.
36. Kamada N., Davies H.S., Roser B. Reversal of transplantation immunity by liver grafting. Nature 1981, 292(5826):840-842.
37. Assy N., Adams P.C., Myers P., et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation 2007, 83(12):1571-1576.
38. Devlin J., Doherty D., Thomson L., et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998, 27(4):926-933.
39. Eason J.D., Cohen A.J., Nair S., et al. Tolerance: is it worth the risk?. Transplantation 2005, 79(9):1157-1159.
40. Girlanda R., Rela M., Williams R., et al. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 2005, 37(4):1708-1709.
41. Martinez-Llordella M., Puig-Pey I., Orlando G., et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007, 7(2):309-319.
42. Mazariegos G.V., Reyes J., Marino I.R., et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997, 63(2):243-249.
43. Orlando G., Manzia T., Baiocchi L., et al. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 2008, 20(1-2):43-47.
44. Ramos H.C., Reyes J., Abu-Elmagd K., et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995, 59(2):212-217.
45. Sandborn W.J., Hay J.E., Porayko M.K., et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994, 19(4):925-932.
46. Takatsuki M., Uemoto S., Inomata Y., et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001, 72(3):449-454.
47. Tisone G., Orlando G., Cardillo A., et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006, 44(4):702-709.
48. Tryphonopoulos P., Tzakis A.G., Weppler D., et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 2005, 5(3):608-613.
49. Starzl T.E., Demetris A.J., Trucco M., et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993, 17(6):1127-1152.
50. Li Y., Koshiba T., Yoshizawa A., et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004, 4(12):2118-2125.
51. Koshiba T., Li Y., Takemura M., et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007, 17(2):94-97.
52. Martinez-Llordella M., Lozano J.J., Puig-Pey I., et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008, 118(8):2845-2857.
53. Pons J.A., Yelamos J., Ramirez P., et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 2003, 75(7):1045-1047.
54. Mazariegos G.V., Sindhi R., Thomson A.W., et al. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol 2007, 17(2):114-119.
55. Mazariegos G.V. Withdrawal of immunosuppression in liver transplantation: lessons learned from PTLD. Pediatr Transplant 2004, 8(3):210-213.
56. Demetris A.J., Lunz J.G., Randhawa P., et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009, 22(1):120-141.
57. Evans H.M., Kelly D.A., McKiernan P.J., et al. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006, 43(5):1109-1117.
58. Brouard S., Dupont A., Giral M., et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005, 5(2):330-340.
59. Seyfert-Margolis V., Turka L.A. Marking a path to transplant tolerance. J Clin Invest 2008, 118(8):2684-2686.